Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy

Fan Yang, Rui Liu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Haifeng Wu, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 5484.

https://doi.org/10.1182/blood-2025-5484

Published: 2025

Journal Articles

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Danyang Li, Biping Deng, Qinlong Zheng, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 7259.

https://doi.org/10.1182/blood-2025-7259

Published: 2025

Journal Articles

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 672.

https://doi.org/10.1182/blood-2025-672

Published: 2025

Journal Articles

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies

Tingting Yang, Mingming Zhang, Mengqi Yu, Shan Fu, Jingjing Feng, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Zhang, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2025-1040

Published: 2025

Journal Articles

Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma

Mingming Zhang, Lianxuan Liu, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Zhang, He Huang

Blood (2025) 146 (Supplement 1): 1940.

https://doi.org/10.1182/blood-2025-1940

Published: 2025

Journal Articles

Immune remodeling enables sustained EBV clearance in B-cell and plasma cell malignancies after anti-CD19/BCMA CAR-T therapy: A post-hoc analysis

Shuyang Wang, Qisan Wu, Mengmeng Huang, Mingming Zhang, Shan Fu, Tingting Yang, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Zhang, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 2381.

https://doi.org/10.1182/blood-2025-2381

Published: 2025

Journal Articles

The ratio of post-infusion circulating PD-1+ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma

Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Shilin Gan, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 2377.

https://doi.org/10.1182/blood-2025-2377

Published: 2025

Journal Articles

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

Fan Yang, Rui Liu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Haifeng Wu, Alex H. Zhang, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 2368.

https://doi.org/10.1182/blood-2025-2368

Published: 2025

Journal Articles

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Miaomiao Cao, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2025-3708

Published: 2025

Journal Articles

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

Rui Liu, Danyang Li, Zhonghua Fu, Fan Yang, Miaomiao Cao, Lixia Ma, Yuelu Guo, Alex H. Zhang, Biping Deng, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 3706.

https://doi.org/10.1182/blood-2025-3706

Published: 2025

Journal Articles

Anti-CD7 CAR-T cells in patients with relapsed or refractory CD7+ Acute Myeloid Leukemia: First-in-human phase I study

Lianxuan Liu, Mingming Zhang, Houli Zhao, Guoqing Wei, Alex H. Zhang, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 4161.

https://doi.org/10.1182/blood-2025-4161

Published: 2025

Journal Articles

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

Miaomiao Cao, Hui Shi, Danyang Li, Rui Liu, Zhonghua Fu, Fan Yang, Lixia Ma, Yuelu Guo, Biping Deng, Alex H. Zhang, Qinlong Zheng, Xiaoyan Ke, Kai Hu

Blood (2025) 146 (Supplement 1): 5489.

https://doi.org/10.1182/blood-2025-5489

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy

Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL

Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies

Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma

Immune remodeling enables sustained EBV clearance in B-cell and plasma cell malignancies after anti-CD19/BCMA CAR-T therapy: A post-hoc analysis

The ratio of post-infusion circulating PD-1+ CAR-T subsets to product PD-1+ CAR-T cells serves as a predictive biomarker for long-term disease control in CAR T-cell therapy for R/R B-cell lymphoma

CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: Single-arm, open-label, phase I study

CAR-t cell therapy in TP53-mutated CNS lymphoma: Overcoming a high-risk genetic barrier

Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma

Anti-CD7 CAR-T cells in patients with relapsed or refractory CD7+ Acute Myeloid Leukemia: First-in-human phase I study

Genomic heterogeneity and prognostic implications in CAR-t-treated relapsed/refractory primary CNS lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only